MannKind Stock - analyst consensus and long-term outlook

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 15:55 UTC. Details in the imprint.

MannKind (US5638651064) focuses today on its analyst consensus and long-term business profile rather than a fresh company announcement. With no new SEC filing or major press release in the past day, investor attention shifts to estimates, pipeline and revenue drivers.

What current estimates show

According to recent consensus data aggregated by MarketWatch and other financial portals, MannKind is expected to grow revenue in the low double digits in the coming years, driven mainly by Tyvaso DPI and Afrezza royalties.

Analysts also model ongoing operating losses but narrowing adjusted losses per share as scale effects from United Therapeutics collaborations feed through the income statement. The number of active analyst ratings on the stock remains limited for a Nasdaq-listed biotech.

Analyst stance and rating distribution

Recent rating overviews compiled on Yahoo Finance and similar platforms show a small group of covering analysts with a mixed stance between Buy and Hold on MannKind shares, with no major house downgrade or upgrade reported in the last few days.

Average 12-month price targets cited on these portals imply upside from the current share price, but figures vary meaningfully between firms, underlining the uncertainty typical for smaller healthcare names. No new formal research note from a bulge-bracket bank was posted today.

How MannKind makes its money

MannKind focuses on inhaled therapeutics, notably the rapid-acting inhaled insulin Afrezza and the dry powder formulation technology used for Tyvaso DPI for pulmonary arterial hypertension, which is marketed by United Therapeutics with MannKind receiving manufacturing revenue and royalties.

Where the stock trades today

The shares of MannKind (US5638651064) trade on Nasdaq at $5.12 as of 06/20/2026, 15:55 UTC.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.